



Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001-2015 Certified Company

CIN No. : L24239MH1988PLC047759

SYNCOM/SE/2023-24

21st August, 2023

Online filing at: www.listing.bseindia.com and
<https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp>

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai (M.H.) 400 001
BSE CODE:524470

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400051
NSE SYMBOL: SYNCOMF

Sub: Pursuant to the Regulation 30 of SEBI (LODR) Regulations, 2015 for Capacity addition/Expansion.

Dear Sir/Ma'am,

This has in reference to our letter no. SYNCOM/SE/2023-24, SYNCOM/SE/2023-24, SYNCOM/SE/2022-23 and SYNCOM/SE/2020-21 dated 1st July, 2023, 29th May, 2023, 15th September, 2022 and 18th December, 2020 respectively for disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 by which it was informed about our project for expansion cum Modernization of the Company's existing plant from 256-257, Industrial Area Sector I Pithampur, District Dhar (M.P.) 454775.

After months of meticulous planning, diligent execution, and unwavering dedication of our team, we hereby announce that we have commenced our commercial production w.e.f. **21st August, 2023 (Monday)**.

As a result, our capacity has been increased from 200.00 Lakhs to 300.00 Lakhs in Injection.

We will ensure timely compliance with all necessary regulatory requirements and promptly update on any relevant developments as we progress.

We request you to please take the above information on your record.

Thanking You,
Yours faithfully,

For, SYNCOM FORMULATIONS (INDIA) LIMITED

KB


KEDARMAL SHANKARLAL BANKDA
CHAIRMAN AND WHOLE-TIME DIRECTOR
DIN: 00023050

Bringing a smile on every face...